Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Samwel Gesase; Roly D Gosling; Ramadhan Hashim; Rosalynn Ord; Inbarani Naidoo; Rashid Madebe; Jacklin F Mosha; Angel Joho; Victor Mandia; Hedwiga Mrema; Ephraim Mapunda; Zacharia Savael; Martha Lemnge; Frank W Mosha; Brian Greenwood; Cally Roper; Daniel Chandramohan
Publisher: Public Library of Science (PLoS)
Journal: PLoS ONE
Languages: English
Types: Article
Subjects: Infectious Diseases/Epidemiology and Control of Infectious Diseases, Research Article, Infectious Diseases/Tropical and Travel-Associated Diseases, Public Health and Epidemiology/Infectious Diseases, Medicine, Public Health and Epidemiology/Epidemiology, Q, R, Infectious Diseases/Protozoal Infections, Science, Microbiology/Parasitology, Infectious Diseases/Antimicrobials and Drug Resistance, Public Health and Epidemiology/Global Health

Classified by OpenAIRE into

mesheuropmc: parasitic diseases
BACKGROUND: Sulphadoxine-pyrimethamine (SP) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (IPTi). High levels of drug resistance to SP have been reported from north-eastern Tanzania associated with mutations in parasite genes. This study compared the in vivo efficacy of SP in symptomatic 6-59 month children with uncomplicated malaria and in asymptomatic 2-10 month old infants. METHODOLOGY AND PRINCIPAL FINDINGS: An open label single arm (SP) standard 28 day in vivo WHO antimalarial efficacy protocol was used in 6 to 59 months old symptomatic children and a modified protocol used in 2 to 10 months old asymptomatic infants. Enrolment was stopped early (87 in the symptomatic and 25 in the asymptomatic studies) due to the high failure rate. Molecular markers were examined for recrudescence, re-infection and markers of drug resistance and a review of literature of studies looking for the 581G dhps mutation was carried out. In symptomatic children PCR-corrected early treatment failure was 38.8% (95% CI 26.8-50.8) and total failures by day 28 were 82.2% (95% CI 72.5-92.0). There was no significant difference in treatment failures between asymptomatic and symptomatic children. 96% of samples carried parasites with mutations at codons 51, 59 and 108 in the dhfr gene and 63% carried a double mutation at codons 437 and 540. 55% carried a third mutation with the addition of a mutation at codon 581 in the dhps gene. This triple: triple haplotype maybe associated with earlier treatment failure. CONCLUSION: In northern Tanzania SP is a failed drug for treatment and its utility for prophylaxis is doubtful. The study found a new combination of parasite mutations that maybe associated with increased and earlier failure. TRIAL REGISTRATION: ClinicalTrials.gov NCT00361114.

Share - Bookmark

Cite this article